Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QuestCor QSC -- Ignore unavailable to you. Want to Upgrade?

To: roy whitt who wrote (76)	4/14/1998 10:44:00 AM
From: Dennis C	Read Replies (1) \| Respond to of 120

Cypros Pharmaceutical Receives Notice of Allowance on Patent for Use of Cordox in the Treatment of Asthma CARLSBAD, Calif.--(BUSINESS WIRE)--April 14, 1998--Cypros Pharmaceutical Corp. (AMEX:CYP - news) announced today that it received Notice of Allowance from the U.S. Patent and Trademark Office on all claims of a U.S. patent application covering the use of fructose-1,6-diphosphate (FDP) for the treatment of asthma. FDP is the active ingredient in the Cypros drug, Cordox(TM) (formerly CPC-111). The patent covers both inhaled and intravenous routes of Cordox administration. Recent evidence shows that Cordox reduces the immunologic and inflammatory cascade which causes the bronchial constriction and resulting asthma symptoms. The putative mechanism of Cordox action is different from the current steroid and cathecholamine-based asthma drugs and may represent a new and potentially safer way to treat and prevent the asthma episode. Although the current patent is the first obtained by the company specifically for asthma, it complements two existing Cordox patents in other inflammatory and immunologic indications. Cordox has been shown, in various internal and external preclinical studies, to reduce histamine release from activated mast cells, to suppress the activation of lymphocytes, to reduce neutrophil free radical production, and to inhibit interleukin production by activated T-cells. In these studies, Cordox administration directly into the lungs also blocks methacholine-induced asthma attacks. Cypros is developing Cordox as a cytoprotective agent for use in a variety of ischemic indications. The therapeutic properties of Cordox in inflammatory and immunologic indications is a more recent finding and suggests that this natural sugar phosphate may have broader applications. Commenting on the patent, Paul J. Marangos, Ph.D., chairman and chief executive officer of Cypros, stated, ''Cordox augments cellular energy metabolism so it is not surprising that it affects a variety of physiologic processes which underlie multiple diseases. We are making good progress in both discovering these new applications and in establishing the necessary proprietary position to make them commercially viable. Cordox displays many of the properties required for a useful asthma therapeutic; its novel mechanism of action, relative to other treatments, suggests that it may represent a new approach to this widespread and still poorly-treated disorder. Additional studies will determine the potential clinical utility of Cordox in asthma.'' Cypros Pharmaceutical is engaged in the development and marketing of drug products for the hospital market. The company is pursuing a diversified strategy of marketing approved drugs and developing small molecule therapeutics that protect cells from ischemic injury. The company currently has three products on the market, Glofil, Inulin and Ethamolin(R). The company is currently planning Phase III clinical trials for its Cordox and Ceresine drugs, which it expects to commence in 1998.

To: roy whitt who wrote (76)	6/16/1998 2:52:00 PM
From: roy whitt	Read Replies (1) \| Respond to of 120

Cypros Pharmaceutical Corporation Begins A Pivotal Phase III Clinical Trial In Sickle Cell Disease CARLSBAD, Calif.--(BUSINESS WIRE)--June 16, 1998--Cypros Pharmaceutical Corporation (AMEX:CYP) announced today that it has begun recruiting clinical trial sites and chosen a contract research organization to both conduct and manage the Company's first multi-center phase III clinical trial of its Cordox drug in treating the painful vaso-occlusive episode (VOE) of sickle cell disease. The double-blind, placebo-controlled, trial will be conducted at approximately 30 medical centers in the United States and will enroll a total of 280 patients. Endpoints of the study will include pain reduction, length of hospital stay, length of VOE, and amount of narcotic use. Pre-clinical and Phase II clinical results suggest that Cordox treats both the cause of the VOE and the tissue damage that leads to the morbidity and mortality associated with this disease. Commenting on the announcement, Paul J. Marangos, Ph.D., Chairman and Chief Executive Officer, stated, "We are pleased to have reached this milestone of initiating Phase III trials with Cordox. Sickle cell disease, and especially the severely painful vaso-occlusive episode, is a devastating and virtually untreatable disorder. It dramatically reduces both quality and length of life. The cytoprotective effect of Cordox on ischemic tissue, coupled with its ability to reduce red blood cell sickling and improve blood flow, suggest that Cordox may be the first drug therapy to actually treat the cause of the VOE. We are excited about the opportunity of making a potentially positive impact on this disease." Sickle cell disease is the most prevalent genetic disorder worldwide, with carriers numbering about 3-4 million in the United States alone and about 70 - 80,000 having the full manifestation of the disease. A prominent feature of the disorder is recurring vaso-occlusive episodes where deformed (sickled) red blood cells clog blood vessels and starve tissues of oxygen. This causes severe pain and cumulative tissue damage with recurrent episodes and eventually substantial morbidity and mortality. Current treatments for VOE are palliative and involve analgesic therapy with intravenous narcotics. The Cypros drug, Cordox, is a naturally occurring intermediate of anaerobic energy generation in cells. Evidence shows it acts by directly protecting the blood starved (ischemic) tissue, maintaining the red blood cell in its normal shape, and improving blood flow; thereby treating the vaso-occlusive event at its source. Cordox is the first drug with this global physiologically relevant mechanism of action to be tested in sickle cell patients. Sickle cell disease treatment centers, or patients seeking to receive more information on this clinical trial, should contact Catherine Turkel at 760/929-9500 or 888/297-7671. Cypros Pharmaceutical is engaged in the development and marketing of drug products for the hospital market. The Company is pursuing a diversified strategy of marketing approved drugs and developing small molecule therapeutics that protect cells from ischemic injury. The Company currently has three products on the market, Glofil, Inulin and Ethamolin; is preparing to launch two proprietary, extended-release wound-care products; and, is developing its two lead drugs, Cordox and Ceresine, for a variety of ischemic disorders. This news release contains forward-looking statements which involve risks and uncertainties. Such statements are subject to certain factors which may cause the Company's plans to differ. Factors that may cause such differences include, but are not limited to, the risks discussed in the Company's Form 10-K for the fiscal year ended July 31, 1997 and the Risk Factors section of the Company's Registration Statement No. 333-25661. CONTACT: Cypros Pharmaceutical Corporation Paul J. Marangos, Ph.D., 760/929-9500 KEYWORD: CALIFORNIA BW0233 JUN 16,1998